AOC2

Summary

AOC2 (amine oxidase copper containing 2, HGNC:549) is a protein-coding gene on chromosome 17q21.31, encoding Amine oxidase [copper-containing] 2 (O75106). Catalyzes the oxidative deamination of primary amines to the corresponding aldehydes with the concomitant production of hydrogen peroxide and ammonia.

Copper amine oxidases catalyze the oxidative conversion of amines to aldehydes and ammonia in the presence of copper and quinone cofactor. This gene shows high sequence similarity to copper amine oxidases from various species ranging from bacteria to mammals. The protein contains several conserved motifs including the active site of amine oxidases and the histidine residues that likely bind copper. It may be a critical modulator of signal transmission in retina, possibly by degrading the biogenic amines dopamine, histamine, and putrescine. This gene may be a candidate gene for hereditary ocular diseases. Alternate splicing results in multiple transcript variants.

Source: NCBI Gene 314 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 157 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_009590

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:549
Approved symbol	AOC2
Name	amine oxidase copper containing 2
Location	17q21.31
Locus type	gene with protein product
Status	Approved
Aliases	RAO, DAO2
Ensembl gene	ENSG00000131480
Ensembl biotype	protein_coding
OMIM	602268
Entrez	314

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 2 protein_coding

ENST00000253799, ENST00000452774

RefSeq mRNA: 2 — MANE Select: NM_009590 NM_001158, NM_009590

CCDS: CCDS11443, CCDS45690

Canonical transcript exons

ENST00000253799 — 4 exons

Exon	Start	End
ENSE00000899067	42849086	42849371
ENSE00000899068	42849601	42849730
ENSE00002929042	42850082	42850707
ENSE00002938214	42844580	42846214

Expression profiles

Bgee: expression breadth ubiquitous, 175 present calls, max score 81.65.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.9266 / max 260.6254, expressed in 77 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
161006	0.9266	77

Top tissues by expression

293 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sperm	CL:0000019	81.65	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	80.02	gold quality
male germ cell	CL:0000015	79.01	gold quality
periodontal ligament	UBERON:0008266	76.84	gold quality
secondary oocyte	CL:0000655	75.81	silver quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	73.62	gold quality
blood	UBERON:0000178	71.37	gold quality
cartilage tissue	UBERON:0002418	69.91	gold quality
oocyte	CL:0000023	69.78	silver quality
tibia	UBERON:0000979	69.60	silver quality
right lobe of liver	UBERON:0001114	69.32	gold quality
subcutaneous adipose tissue	UBERON:0002190	68.98	gold quality
adipose tissue	UBERON:0001013	68.92	gold quality
omental fat pad	UBERON:0010414	68.88	gold quality
right lung	UBERON:0002167	68.81	gold quality
peritoneum	UBERON:0002358	68.80	gold quality
adipose tissue of abdominal region	UBERON:0007808	68.63	gold quality
connective tissue	UBERON:0002384	67.97	gold quality
right testis	UBERON:0004534	67.18	gold quality
left testis	UBERON:0004533	67.09	gold quality
granulocyte	CL:0000094	66.76	gold quality
cerebellar hemisphere	UBERON:0002245	66.52	gold quality
cerebellar cortex	UBERON:0002129	66.39	gold quality
right hemisphere of cerebellum	UBERON:0014890	66.17	gold quality
gastrocnemius	UBERON:0001388	65.90	gold quality
upper lobe of left lung	UBERON:0008952	65.44	gold quality
testis	UBERON:0000473	65.24	gold quality
lower esophagus mucosa	UBERON:0035834	64.88	gold quality
muscle of leg	UBERON:0001383	64.36	gold quality
cerebellum	UBERON:0002037	64.22	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.57

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

27 targeting AOC2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-6844	99.82	70.69	2423
HSA-MIR-6842-5P	99.80	67.54	1587
HSA-MIR-7110-5P	99.80	67.84	1712
HSA-MIR-6751-5P	99.56	64.99	1145
HSA-MIR-143-3P	99.49	69.05	1457
HSA-MIR-4770	99.49	69.09	1451
HSA-MIR-6088	99.29	68.45	1284
HSA-MIR-5589-3P	99.29	68.30	1443
HSA-MIR-6803-5P	99.19	63.90	1026
HSA-MIR-3199	99.17	65.19	696
HSA-MIR-8052	99.17	65.01	719
HSA-MIR-3145-3P	98.85	69.07	2031
HSA-MIR-4700-5P	98.63	67.43	1915
HSA-MIR-654-3P	98.38	67.61	905
HSA-MIR-3689A-5P	98.35	70.12	1049
HSA-MIR-3689B-5P	98.35	70.12	1049
HSA-MIR-3689E	98.35	70.12	1049
HSA-MIR-3689F	98.35	70.08	1052
HSA-MIR-4303	98.01	68.13	2304
HSA-MIR-8089	97.74	66.21	1698
HSA-MIR-3928-3P	97.61	66.53	1096
HSA-MIR-4667-5P	97.61	66.67	1683
HSA-MIR-939-5P	97.10	65.80	1579
HSA-MIR-1343-5P	96.48	66.06	1506
HSA-MIR-6734-5P	95.70	65.56	950

Literature-anchored findings (GeneRIF, showing 2)

• AOC2 mRNA is expressed in many tissues, however, the only tissues with detectable AOC2-like enzyme activity is found in the eye. (PMID:19588076)
• Adipose tissue SSAO activity did not vary according to anatomical location and/or metabolic status in severely obese women. (PMID:27766585)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
danio_rerio	aoc2	ENSDARG00000014646
mus_musculus	Aoc2	ENSMUSG00000078651

Paralogs (2): AOC1 (ENSG00000002726), AOC3 (ENSG00000131471)

Protein

Protein identifiers

Amine oxidase [copper-containing] 2 — O75106 (reviewed: O75106)

Alternative names: Amine oxidase copper-containing 2, Retina-specific copper amine oxidase, Semicarbazide-sensitive amine oxidase

All UniProt accessions (1): O75106

UniProt curated annotations — full annotation on UniProt →

Function. Catalyzes the oxidative deamination of primary amines to the corresponding aldehydes with the concomitant production of hydrogen peroxide and ammonia. Has a preference for 2-phenylethylamine, tryptamine and tyramine. Could also act on methylamine and benzylamine but much less efficiently.

Subunit / interactions. Homodimer; disulfide-linked. Probably forms heterodimers with AOC3.

Subcellular location. Cell membrane Cytoplasm.

Tissue specificity. Expressed in many tissues including adipocytes with higher expression in retina where it is active. Not expressed in testis. Not expressed in thymus.

Post-translational modifications. Topaquinone (TPQ) is generated by copper-dependent autoxidation of a specific tyrosyl residue.

Cofactor. Binds 1 copper ion per subunit. Binds 2 calcium ions per subunit. Contains 1 topaquinone per subunit.

Induction. Up-regulated during in vitro adipocyte differentiation.

Similarity. Belongs to the copper/topaquinone oxidase family.

Isoforms (2)

UniProt ID	Names	Canonical?
O75106-1	1, Long	yes
O75106-2	2, Short

RefSeq proteins (2): NP_001149, NP_033720* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000269	Cu_amine_oxidase	Family
IPR015798	Cu_amine_oxidase_C	Domain
IPR015800	Cu_amine_oxidase_N2	Domain
IPR015802	Cu_amine_oxidase_N3	Domain
IPR016182	Cu_amine_oxidase_N-reg	Homologous_superfamily
IPR036460	Cu_amine_oxidase_C_sf	Homologous_superfamily
IPR049947	Cu_Am_Ox_Cu-bd	Conserved_site
IPR049948	Cu_Am_ox_TPQ-bd	Conserved_site

Pfam: PF01179, PF02727, PF02728

Enzyme classification (BRENDA):

• EC 1.4.3.21 — primary-amine oxidase (BRENDA: 28 organisms, 170 substrates, 291 inhibitors, 129 Km, 92 kcat entries)

Substrate kinetics (BRENDA)

35 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
BENZYLAMINE	0.0013–2.38	24
2-PHENYLETHYLAMINE	0.0012–1.94	14
METHYLAMINE	0.01–2.043	13
BETA-PHENYLETHYLAMINE	0.0009–0.028	11
TYRAMINE	0.0104–1.92	8
O2	0.0163–1	6
HISTAMINE	0.28–0.88	4
PUTRESCINE	0.038–1.2	4
AMYLAMINE	0.11–5.71	3
BUTYLAMINE	0.32–2.83	3
CADAVERINE	0.089–12.7	3
HEXAKIS(BENZYLAMMONIUM) DECAVANADATE (V) DIHYDRA	0.014–0.213	3
SPERMIDINE	0.348–7.04	3
DOPAMINE	0.099–0.1	2
ETHYLAMINE	0.86–12.8	2

Catalyzed reactions (Rhea), 3 shown:

• 2-phenylethylamine + O2 + H2O = 2-phenylacetaldehyde + H2O2 + NH4(+) (RHEA:25265)
• tyramine + O2 + H2O = (4-hydroxyphenyl)acetaldehyde + H2O2 + NH4(+) (RHEA:30591)
• tryptamine + O2 + H2O = indole-3-acetaldehyde + H2O2 + NH4(+) (RHEA:59416)

UniProt features (37 total): binding site 13, sequence variant 5, glycosylation site 4, sequence conflict 4, disulfide bond 3, topological domain 2, active site 2, chain 1, modified residue 1, transmembrane region 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O75106-F1	94.10	0.88

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (2): 380 (proton acceptor); 465 (schiff-base intermediate with substrate; via topaquinone)

Ligand- & substrate-binding residues (13): 527; 568; 637; 659; 661; 663; 669; 670; 680; 516; 518; 525 …

Post-translational modifications (1): 465

Disulfide bonds (3): 398–424, 730–737, 744

Glycosylation sites (4): 133, 198, 226, 662

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-211945	Phase I - Functionalization of compounds
R-HSA-1430728	Metabolism
R-HSA-211859	Biological oxidations

MSigDB gene sets: 89 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_BRAIN_TUMORAL_MACROPHAGE_UP, GSE18804_BRAIN_VS_COLON_TUMORAL_MACROPHAGE_UP, GOBP_PHENOL_CONTAINING_COMPOUND_METABOLIC_PROCESS, REACTOME_BIOLOGICAL_OXIDATIONS, WANG_CLIM2_TARGETS_UP, RORA1_01, BROWNE_HCMV_INFECTION_8HR_UP, TGACCTY_ERR1_Q2, HNF1_Q6, NKX61_01, MCLACHLAN_DENTAL_CARIES_DN, BLALOCK_ALZHEIMERS_DISEASE_UP, BRN2_01, GOBP_SENSORY_PERCEPTION_OF_LIGHT_STIMULUS, TGACATY_UNKNOWN

GO Biological Process (4): catecholamine metabolic process (GO:0006584), xenobiotic metabolic process (GO:0006805), visual perception (GO:0007601), amine metabolic process (GO:0009308)

GO Molecular Function (7): copper ion binding (GO:0005507), primary methylamine oxidase activity (GO:0008131), electron transfer activity (GO:0009055), quinone binding (GO:0048038), protein binding (GO:0005515), oxidoreductase activity (GO:0016491), metal ion binding (GO:0046872)

GO Cellular Component (3): cytoplasm (GO:0005737), plasma membrane (GO:0005886), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Biological oxidations	1
Metabolism	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
metabolic process	2
cellular anatomical structure	2
biogenic amine metabolic process	1
catechol-containing compound metabolic process	1
cellular response to xenobiotic stimulus	1
sensory perception of light stimulus	1
transition metal ion binding	1
oxidoreductase activity, acting on the CH-NH2 group of donors, oxygen as acceptor	1
molecular_function	1
small molecule binding	1
binding	1
catalytic activity	1
cation binding	1
intracellular anatomical structure	1
membrane	1
cell periphery	1

Protein interactions and networks

STRING

1126 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
AOC2	MAOA	P21397	798
AOC2	MAOB	P27338	794
AOC2	GNGT2	O14610	778
AOC2	PDE6G	P18545	650
AOC2	TIMP2	P16035	639
AOC2	ALDH2	P05091	591
AOC2	PRPH2	P23942	590
AOC2	ITGAL	P20701	548
AOC2	ACADL	P28330	446
AOC2	GPD1L	Q8N335	446
AOC2	RHO	P08100	445
AOC2	CPT2	P23786	414
AOC2	INS	P01308	413
AOC2	ENPP2	Q13822	412
AOC2	DAO	P14920	410

IntAct

12 interactions, top by confidence:

A	B	Type	Score
AOC2	AQP6	psi-mi:“MI:0915”(physical association)	0.560
AOC2	ERGIC3	psi-mi:“MI:0915”(physical association)	0.560
AOC3	AOC2	psi-mi:“MI:0914”(association)	0.530
AOC2	GOLGA5	psi-mi:“MI:0914”(association)	0.530
CCDC144BP	AOC2	psi-mi:“MI:0914”(association)	0.350
AOC2	YIF1A	psi-mi:“MI:0914”(association)	0.350
AOC2	AQP6	psi-mi:“MI:0915”(physical association)	0.000
AOC2	ERGIC3	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (15): AOC2 (Affinity Capture-RNA), AOC2 (Affinity Capture-RNA), AOC2 (Affinity Capture-MS), LEMD3 (Affinity Capture-MS), GOLGA5 (Affinity Capture-MS), AOC2 (Two-hybrid), AOC2 (Two-hybrid), AOC2 (Affinity Capture-RNA), AOC2 (Affinity Capture-MS), SMURF2 (Affinity Capture-MS), GOLGA5 (Affinity Capture-MS), YIF1A (Affinity Capture-MS), AOC2 (Affinity Capture-MS), LEMD3 (Affinity Capture-MS), AOC2 (Affinity Capture-RNA)

ESM2 similar proteins: A6QQ07, F1M928, H2A0M3, O00115, O08590, O15547, O23349, O46406, O54782, O62855, O70423, O75106, O95897, P09172, P0DO00, P10820, P15101, P19801, P36633, P56542, Q04912, Q05685, Q16853, Q28949, Q29437, Q2KHV9, Q3V1N9, Q3V5L5, Q5FVF9, Q5M936, Q5R9I0, Q5RDJ3, Q64237, Q6MG64, Q765H6, Q812C9, Q8H1H9, Q8JZQ5, Q91X21, Q9DBX3

Diamond homologs: H2A0M3, O08590, O46406, O70423, O75106, P19801, P36633, Q16853, Q29437, Q5R9I0, Q812C9, Q8JZQ5, Q9TRC7, Q9TTK6, O23349

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

157 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	138
Likely benign	6
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

606 predictions. Top by Δscore:

Variant	Effect	Δscore
17:42849199:G:GT	donor_gain	1.0000
17:42849224:G:GT	donor_gain	1.0000
17:42849224:G:T	donor_gain	1.0000
17:42849195:A:T	donor_gain	0.9900
17:42849202:G:GT	donor_gain	0.9900
17:42849338:A:T	donor_gain	0.9900
17:42849594:T:A	acceptor_gain	0.9900
17:42846210:GGCAG:G	donor_gain	0.9800
17:42846211:GCAGG:G	donor_gain	0.9800
17:42846215:G:A	donor_loss	0.9800
17:42846216:T:G	donor_loss	0.9800
17:42849587:T:TA	acceptor_gain	0.9800
17:42850076:TTGCA:T	acceptor_loss	0.9800
17:42850077:TGCA:T	acceptor_loss	0.9800
17:42850078:GCA:G	acceptor_loss	0.9800
17:42850079:CA:C	acceptor_loss	0.9800
17:42850080:AGGA:A	acceptor_loss	0.9800
17:42846211:GCAG:G	donor_gain	0.9700
17:42846215:G:GG	donor_gain	0.9700
17:42849350:A:T	donor_gain	0.9700
17:42849369:G:T	donor_gain	0.9700
17:42849727:A:T	donor_gain	0.9700
17:42850080:AG:A	acceptor_gain	0.9700
17:42850081:GG:G	acceptor_gain	0.9700
17:42849080:TGGCA:T	acceptor_loss	0.9600
17:42849081:GGCA:G	acceptor_loss	0.9600
17:42849082:GCA:G	acceptor_loss	0.9600
17:42849083:CA:C	acceptor_loss	0.9600
17:42849084:A:AT	acceptor_loss	0.9600
17:42849084:AG:A	acceptor_gain	0.9600

AlphaMissense

4878 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:42844932:G:C	K102N	0.982
17:42844932:G:T	K102N	0.982
17:42845902:T:C	F426L	0.980
17:42845904:T:A	F426L	0.980
17:42845904:T:G	F426L	0.980
17:42845993:T:A	V456D	0.980
17:42849644:A:C	S640R	0.979
17:42849646:C:A	S640R	0.979
17:42849646:C:G	S640R	0.979
17:42849292:T:G	Y599D	0.975
17:42850133:G:C	D686H	0.975
17:42850094:T:A	W673R	0.972
17:42850094:T:C	W673R	0.972
17:42845818:T:C	C398R	0.971
17:42845898:T:G	C424W	0.970
17:42845998:T:C	S458P	0.970
17:42846031:T:A	W469R	0.970
17:42846031:T:C	W469R	0.970
17:42845820:C:G	C398W	0.969
17:42845611:T:A	W329R	0.968
17:42845611:T:C	W329R	0.968
17:42846074:T:A	V483D	0.967
17:42845903:T:G	F426C	0.966
17:42845896:T:C	C424R	0.965
17:42845438:T:C	L271S	0.964
17:42845284:T:A	W220R	0.961
17:42845284:T:C	W220R	0.961
17:42845819:G:A	C398Y	0.961
17:42846195:G:C	K523N	0.961
17:42846195:G:T	K523N	0.961

dbSNP variants (sampled 300 via entrez): RS1000783537 (17:42845513 T>C), RS1001429718 (17:42848897 C>T), RS1001795441 (17:42848391 G>T), RS1002213011 (17:42849205 C>T), RS1002688298 (17:42843613 T>C), RS1002860776 (17:42846951 G>A,C), RS1002892903 (17:42845948 T>G), RS1003276317 (17:42844956 C>G), RS1003901233 (17:42844562 G>A,T), RS1004652664 (17:42847993 A>G), RS1004747441 (17:42847775 C>A,T), RS1006238544 (17:42845491 C>G,T), RS1007067864 (17:42848205 G>C), RS1007134415 (17:42842753 G>A,C), RS1007486638 (17:42846451 C>T)

Disease associations

OMIM: gene MIM:602268 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4112 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 84 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL489079	MOFEGILINE	2	84

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

138 potent at pChembl≥5 of 142 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.40	IC50	4	nM	CHEMBL5198317
8.30	IC50	5	nM	CHEMBL5204901
8.22	IC50	6	nM	CHEMBL5201033
8.00	IC50	10	nM	MOFEGILINE
7.96	IC50	11	nM	CHEMBL5186190
7.92	IC50	12	nM	CHEMBL5197971
7.72	IC50	19	nM	CHEMBL5194056
7.72	IC50	19	nM	CHEMBL5196906
7.54	IC50	29	nM	CHEMBL5196906
7.50	IC50	32	nM	CHEMBL5186898
7.22	IC50	60	nM	CHEMBL5777093
7.22	IC50	60	nM	CHEMBL5886041
7.22	IC50	60	nM	CHEMBL5828442
7.22	IC50	60	nM	CHEMBL5744148
7.22	IC50	60	nM	CHEMBL5933351
7.22	IC50	60	nM	CHEMBL6027724
7.22	IC50	60	nM	CHEMBL5816077
7.22	IC50	60	nM	CHEMBL5808263
7.22	IC50	60	nM	CHEMBL5918877
7.22	IC50	60	nM	CHEMBL5782023
7.22	IC50	60	nM	CHEMBL5980936
7.22	IC50	60	nM	CHEMBL5817720
7.22	IC50	60	nM	CHEMBL6035838
7.22	IC50	60	nM	CHEMBL5898105
7.22	IC50	60	nM	CHEMBL6003547
7.22	IC50	60	nM	CHEMBL5808939
7.22	IC50	60	nM	CHEMBL5890035
7.22	IC50	60	nM	CHEMBL5857963
7.22	IC50	60	nM	CHEMBL5801781
7.22	IC50	60	nM	CHEMBL5976333
7.22	IC50	60	nM	CHEMBL5902745
7.22	IC50	60	nM	CHEMBL5935473
7.22	IC50	60	nM	CHEMBL5989675
7.22	IC50	60	nM	CHEMBL5845697
7.22	IC50	60	nM	CHEMBL5752566
7.22	IC50	60	nM	CHEMBL5975280
7.22	IC50	60	nM	CHEMBL5740585
7.22	IC50	60	nM	CHEMBL5759148
7.22	IC50	60	nM	CHEMBL5772933
7.22	IC50	60	nM	CHEMBL5863149
7.22	IC50	60	nM	CHEMBL5939154
7.22	IC50	60	nM	CHEMBL5940708
7.22	IC50	60	nM	CHEMBL5944255
7.22	IC50	60	nM	CHEMBL5826991
7.22	IC50	60	nM	CHEMBL6015222
7.22	IC50	60	nM	CHEMBL5866280
7.22	IC50	60	nM	CHEMBL5922568
7.22	IC50	60	nM	CHEMBL5799590
7.22	IC50	60	nM	CHEMBL5869849
7.22	IC50	60	nM	CHEMBL5999718

PubChem BioAssay actives

32 with measured affinity, of 42 total; 16 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
3-fluoro-2-[(4-fluorophenoxy)methyl]prop-2-en-1-amine	1851790: Inhibition of recombinant human SSAO	ic50	0.0040	uM
(Z)-2-[(2S)-2,3-dihydro-1-benzofuran-2-yl]-3-fluoroprop-2-en-1-amine;hydrochloride	1851790: Inhibition of recombinant human SSAO	ic50	0.0050	uM
3-fluoro-2-(phenoxymethyl)prop-2-en-1-amine	1851790: Inhibition of recombinant human SSAO	ic50	0.0060	uM
(2E)-2-(fluoromethylidene)-4-(4-fluorophenyl)butan-1-amine	1851790: Inhibition of recombinant human SSAO	ic50	0.0100	uM
(E)-2-[(2S)-2,3-dihydro-1-benzofuran-2-yl]-3-fluoroprop-2-en-1-amine;hydrochloride	1851790: Inhibition of recombinant human SSAO	ic50	0.0110	uM
2-(2,3-dihydro-1-benzofuran-2-yl)-3-fluoroprop-2-en-1-amine;hydrochloride	1851790: Inhibition of recombinant human SSAO	ic50	0.0120	uM
(E)-3-fluoro-2-(phenoxymethyl)prop-2-en-1-amine	1851790: Inhibition of recombinant human SSAO	ic50	0.0190	uM
(E)-2-[(2R)-2,3-dihydro-1-benzofuran-2-yl]-3-fluoroprop-2-en-1-amine;hydrochloride	1851790: Inhibition of recombinant human SSAO	ic50	0.0190	uM
(Z)-2-[(2R)-2,3-dihydro-1-benzofuran-2-yl]-3-fluoroprop-2-en-1-amine;hydrochloride	1851790: Inhibition of recombinant human SSAO	ic50	0.0320	uM
2-(3-pyrrol-1-ylphenyl)acetohydrazide	159992: Effect on plasma amine oxidase (0.1 uM) after 15 min of incubation at pH 7.2	ic50	0.1000	uM
2-(4-pyrrol-1-ylphenyl)acetohydrazide	159992: Effect on plasma amine oxidase (0.1 uM) after 15 min of incubation at pH 7.2	ic50	0.1000	uM
N-(propan-2-ylideneamino)-2-(4-pyrrol-1-ylphenyl)acetamide	159993: Effect on plasma amine oxidase (0.1 uM) after 30 min of incubation at pH 7.2	ic50	0.1000	uM
(E)-3-fluoro-2-[(2-methylphenoxy)methyl]prop-2-en-1-amine	1851790: Inhibition of recombinant human SSAO	ic50	0.2880	uM
4-pyrrol-1-ylbenzohydrazide	159993: Effect on plasma amine oxidase (0.1 uM) after 30 min of incubation at pH 7.2	ic50	5.0000	uM
2-[4-(2,5-dimethylpyrrol-1-yl)phenyl]acetohydrazide	159992: Effect on plasma amine oxidase (0.1 uM) after 15 min of incubation at pH 7.2	ic50	10.0000	uM
3-pyrrol-1-ylbenzohydrazide	159993: Effect on plasma amine oxidase (0.1 uM) after 30 min of incubation at pH 7.2	ic50	10.0000	uM

CTD chemical–gene interactions

37 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Air Pollutants	affects expression, increases abundance, increases expression	2
Formaldehyde	increases expression	2
aristolochic acid I	increases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	decreases expression	1
tris(2-butoxyethyl) phosphate	affects expression	1
2,4,5,2’,4’,5’-hexachlorobiphenyl	decreases expression	1
sulforaphane	increases expression	1
3,4,5,3’,4’-pentachlorobiphenyl	decreases expression	1
perfluorooctanoic acid	decreases expression	1
ferrous chloride	increases expression	1
di-n-butylphosphoric acid	affects expression	1
pentabromodiphenyl ether	increases expression	1
CGP 52608	affects binding, increases reaction	1
abrine	increases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
jinfukang	affects cotreatment, decreases expression	1
NSC 689534	affects binding, increases expression	1
PCI 5002	affects cotreatment, increases expression	1
2,3,5-trichloro-6-phenyl-(1,4)benzoquinone	decreases expression	1
Benzo(a)pyrene	affects methylation	1
Cisplatin	decreases expression, affects cotreatment	1
Copper	affects binding, increases expression	1
Dichlorodiphenyl Dichloroethylene	decreases expression	1
Environmental Pollutants	affects expression	1
Ozone	affects expression, increases abundance	1
Quercetin	increases expression	1
Silicon Dioxide	increases expression	1
Smoke	decreases expression	1
Tobacco Smoke Pollution	increases expression	1

ChEMBL screening assays

13 unique, capped per target: 13 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL2034564	Binding	Inhibition of human AOC2	The discovery and development of selective 3-fluoro-4-aryloxyallylamine inhibitors of the amine oxidase activity of semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 (SSAO/VAP-1). — Bioorg Med Chem Lett

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.